α2-Adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production

S. B. Jones, Myron Lee Toews, J. T. Turner, D. B. Bylund

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Preincubation of HT29 human colonic adenocarcinoma cells with α2-adrenergic agonists resulted in a 10- to 20-fold increase in forskolin-stimulated cyclic AMP production as compared to cells preincubated without agonist. Similar results were obtained using either a [3H]adenine prelabeling assay or a cyclic AMP radioimmunoassay to measure cyclic AMP levels. This phenomenon, which is termed sensitization, is α2-adrenergic receptor-mediated and rapid in onset and reversal. Yohimbine, an α2-adrenergic receptor-selective antagonist, blocked norepinephrine-induced sensitization, whereas prazosin (α1-adrenergic) and sotalol (β-adrenergic) did not. The time for half-maximal sensitization was 5 min and the half-time for reversal was 10 min. Only a 2-fold sensitization of cyclic AMP production stimulated by vasoactive intestinal peptide was observed, indicating that sensitization is relatively selective for forskolin. Sensitization reflects an increased production of cyclic AMP and not a decreased degradation of cyclic AMP, since incubation with a phosphodiesterase inhibitor and forskolin did not mimic sensitization. Increasing the levels of cyclic AMP during the preincubation (using a phosphodiesterase inhibitor) had no effect on sensitization, indicating that sensitization is not caused by decreased cyclic AMP levels during the preincubation. This rapid and dramatic sensitization of forskolin-stimulated cyclic AMP production is a previously unreported effect that can be added to the growing list of α2-adrenergic responses that are not mediated by a decrease in cyclic AMP.

Original languageEnglish (US)
Pages (from-to)1294-1298
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume84
Issue number5
DOIs
StatePublished - Jan 1 1987

Fingerprint

Colforsin
Cyclic AMP
Adrenergic Receptors
Phosphodiesterase Inhibitors
Adrenergic Agents
Sotalol
Adrenergic Agonists
Adrenergic Antagonists
Yohimbine
Prazosin
Vasoactive Intestinal Peptide
Adenine
Radioimmunoassay
Norepinephrine
Adenocarcinoma

ASJC Scopus subject areas

  • General

Cite this

α2-Adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production. / Jones, S. B.; Toews, Myron Lee; Turner, J. T.; Bylund, D. B.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, No. 5, 01.01.1987, p. 1294-1298.

Research output: Contribution to journalArticle

@article{ac0b569c85074ce58e4ab7163986194b,
title = "α2-Adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production",
abstract = "Preincubation of HT29 human colonic adenocarcinoma cells with α2-adrenergic agonists resulted in a 10- to 20-fold increase in forskolin-stimulated cyclic AMP production as compared to cells preincubated without agonist. Similar results were obtained using either a [3H]adenine prelabeling assay or a cyclic AMP radioimmunoassay to measure cyclic AMP levels. This phenomenon, which is termed sensitization, is α2-adrenergic receptor-mediated and rapid in onset and reversal. Yohimbine, an α2-adrenergic receptor-selective antagonist, blocked norepinephrine-induced sensitization, whereas prazosin (α1-adrenergic) and sotalol (β-adrenergic) did not. The time for half-maximal sensitization was 5 min and the half-time for reversal was 10 min. Only a 2-fold sensitization of cyclic AMP production stimulated by vasoactive intestinal peptide was observed, indicating that sensitization is relatively selective for forskolin. Sensitization reflects an increased production of cyclic AMP and not a decreased degradation of cyclic AMP, since incubation with a phosphodiesterase inhibitor and forskolin did not mimic sensitization. Increasing the levels of cyclic AMP during the preincubation (using a phosphodiesterase inhibitor) had no effect on sensitization, indicating that sensitization is not caused by decreased cyclic AMP levels during the preincubation. This rapid and dramatic sensitization of forskolin-stimulated cyclic AMP production is a previously unreported effect that can be added to the growing list of α2-adrenergic responses that are not mediated by a decrease in cyclic AMP.",
author = "Jones, {S. B.} and Toews, {Myron Lee} and Turner, {J. T.} and Bylund, {D. B.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1073/pnas.84.5.1294",
language = "English (US)",
volume = "84",
pages = "1294--1298",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "5",

}

TY - JOUR

T1 - α2-Adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production

AU - Jones, S. B.

AU - Toews, Myron Lee

AU - Turner, J. T.

AU - Bylund, D. B.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Preincubation of HT29 human colonic adenocarcinoma cells with α2-adrenergic agonists resulted in a 10- to 20-fold increase in forskolin-stimulated cyclic AMP production as compared to cells preincubated without agonist. Similar results were obtained using either a [3H]adenine prelabeling assay or a cyclic AMP radioimmunoassay to measure cyclic AMP levels. This phenomenon, which is termed sensitization, is α2-adrenergic receptor-mediated and rapid in onset and reversal. Yohimbine, an α2-adrenergic receptor-selective antagonist, blocked norepinephrine-induced sensitization, whereas prazosin (α1-adrenergic) and sotalol (β-adrenergic) did not. The time for half-maximal sensitization was 5 min and the half-time for reversal was 10 min. Only a 2-fold sensitization of cyclic AMP production stimulated by vasoactive intestinal peptide was observed, indicating that sensitization is relatively selective for forskolin. Sensitization reflects an increased production of cyclic AMP and not a decreased degradation of cyclic AMP, since incubation with a phosphodiesterase inhibitor and forskolin did not mimic sensitization. Increasing the levels of cyclic AMP during the preincubation (using a phosphodiesterase inhibitor) had no effect on sensitization, indicating that sensitization is not caused by decreased cyclic AMP levels during the preincubation. This rapid and dramatic sensitization of forskolin-stimulated cyclic AMP production is a previously unreported effect that can be added to the growing list of α2-adrenergic responses that are not mediated by a decrease in cyclic AMP.

AB - Preincubation of HT29 human colonic adenocarcinoma cells with α2-adrenergic agonists resulted in a 10- to 20-fold increase in forskolin-stimulated cyclic AMP production as compared to cells preincubated without agonist. Similar results were obtained using either a [3H]adenine prelabeling assay or a cyclic AMP radioimmunoassay to measure cyclic AMP levels. This phenomenon, which is termed sensitization, is α2-adrenergic receptor-mediated and rapid in onset and reversal. Yohimbine, an α2-adrenergic receptor-selective antagonist, blocked norepinephrine-induced sensitization, whereas prazosin (α1-adrenergic) and sotalol (β-adrenergic) did not. The time for half-maximal sensitization was 5 min and the half-time for reversal was 10 min. Only a 2-fold sensitization of cyclic AMP production stimulated by vasoactive intestinal peptide was observed, indicating that sensitization is relatively selective for forskolin. Sensitization reflects an increased production of cyclic AMP and not a decreased degradation of cyclic AMP, since incubation with a phosphodiesterase inhibitor and forskolin did not mimic sensitization. Increasing the levels of cyclic AMP during the preincubation (using a phosphodiesterase inhibitor) had no effect on sensitization, indicating that sensitization is not caused by decreased cyclic AMP levels during the preincubation. This rapid and dramatic sensitization of forskolin-stimulated cyclic AMP production is a previously unreported effect that can be added to the growing list of α2-adrenergic responses that are not mediated by a decrease in cyclic AMP.

UR - http://www.scopus.com/inward/record.url?scp=0023101457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023101457&partnerID=8YFLogxK

U2 - 10.1073/pnas.84.5.1294

DO - 10.1073/pnas.84.5.1294

M3 - Article

VL - 84

SP - 1294

EP - 1298

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 5

ER -